Comparative Pharmacology
Head-to-head clinical analysis: MOUNJARO versus OZEMPIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOUNJARO versus OZEMPIC.
MOUNJARO vs OZEMPIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It activates GIP and GLP-1 receptors, potentiating glucose-dependent insulin secretion from pancreatic beta cells, reducing glucagon secretion, slowing gastric emptying, and promoting satiety via hypothalamic appetite regulation.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the action of endogenous GLP-1, which increases insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety. The primary mechanism is activation of GLP-1 receptors on pancreatic beta cells, leading to glucose-dependent insulin release.
Subcutaneous injection once weekly. Starting dose: 2.5 mg for 4 weeks, then increase to 5 mg for at least 4 weeks. For additional glycemic control, may increase in 2.5 mg increments after at least 4 weeks on current dose. Maximum dose: 15 mg once weekly.
1 mg subcutaneously once weekly, starting at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly for at least 4 weeks before escalating to 1 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 5 days (range 4-6 days), supporting once-weekly dosing. Achieves steady-state after 4-5 weeks.
Terminal elimination half-life approximately 1 week (5–7 days) in subcutaneous dosing, allowing once-weekly administration. Steady state reached after 4–5 weeks.
Primarily eliminated via proteolytic degradation, with the parent drug not significantly excreted renally or in feces. Small amounts of metabolites may be excreted in urine and feces.
Primarily renal (80%) and biliary/fecal (20%). Unchanged parent drug accounts for ~5-10%; majority is degraded into small peptides/amino acids.
Category C
Category C
Dual GIP/GLP-1 Receptor Agonist
GLP-1 Receptor Agonist